Skip to Main content Skip to Navigation
New interface
Journal articles

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03623734
Contributor : François Bertucci Connect in order to contact the contributor
Submitted on : Tuesday, March 29, 2022 - 6:50:31 PM
Last modification on : Monday, November 28, 2022 - 10:38:07 AM

Identifiers

Citation

Olivier Mir, Claire Cropet, Maud Toulmonde, Axel Le Cesne, Mathieu Molimard, et al.. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncology, 2016, 17 (5), pp.632-641. ⟨10.1016/s1470-2045(16)00075-9⟩. ⟨hal-03623734⟩

Share

Metrics

Record views

13